<\/p>\n
Conimune ME<\/strong> is an oral capsule from Concord Drugs containing cyclosporine 25 mg<\/strong> in the modified microemulsion (ME)<\/strong> formulation — the standard equivalent of Sandimmune Neoral. Cyclosporine is a calcineurin inhibitor<\/strong> that blocks T-cell IL-2 production, broadly suppressing the cellular immune response. Standard adult dose: 2.5–5 mg\/kg\/day in 2 divided doses<\/strong>, titrated to whole-blood trough level (typically 100–300 ng\/mL depending on indication). Used for solid-organ transplant rejection prevention, severe rheumatoid arthritis, severe psoriasis, severe atopic dermatitis, nephrotic syndrome (steroid-resistant), Behçet's disease, severe ulcerative colitis flare, and other severe autoimmune conditions resistant to first-line therapy. Mandatory monitoring before and during therapy: trough cyclosporine level, blood pressure, serum creatinine and urea, magnesium, potassium, fasting lipids, fasting glucose, hepatic enzymes.<\/strong> The drug has a massive interaction surface<\/strong> through CYP3A4 and P-glycoprotein — statins (rhabdomyolysis), grapefruit juice, azole antifungals, macrolide antibiotics, and many anti-epileptics all change cyclosporine levels significantly. Modified microemulsion and original Sandimmune are NOT bioequivalent<\/strong> — never switch formulations without re-checking trough levels.<\/p>\n<\/div>\n <\/p>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n Conimune ME is an oral soft-gelatin capsule manufactured by Concord Drugs containing cyclosporine<\/strong> in the modified microemulsion (ME) formulation — the same delivery system as the originator brand Sandimmune Neoral. Cyclosporine is an 11-amino-acid cyclic peptide originally isolated from the soil fungus Tolypocladium inflatum<\/em> in the 1970s; its discovery transformed solid-organ transplantation by making routine kidney, liver, heart and lung transplant feasible.<\/p>\n Conimune ME is Concord Drugs' branded generic cyclosporine in the modified microemulsion (ME) formulation — the standard equivalent of Sandimmune Neoral. The 25 mg capsule strength is the building block for adult dosing across solid-organ transplant rejection prevention, severe rheumatoid arthritis, severe psoriasis, severe atopic dermatitis, nephrotic syndrome and other severe autoimmune indications.<\/p>\n About the “ME” in the brand name.<\/strong> Cyclosporine is a notoriously hydrophobic molecule and the original Sandimmune oil-based formulation had highly variable, food-dependent absorption. The modified microemulsion (Neoral \/ Sandimmune ME \/ Conimune ME) pre-emulsifies the drug with a self-microemulsifying lipid system, giving much more reliable absorption that is largely independent of bile flow. The two formulations have different bioavailability and are NOT considered bioequivalent<\/strong> — switching between them requires a fresh trough-level check and may need a dose adjustment.<\/p>\n Cyclosporine binds cyclophilin A<\/strong> inside T-lymphocytes; the cyclosporine-cyclophilin complex then inhibits calcineurin<\/strong>, a phosphatase that activates the nuclear factor of activated T-cells (NFAT). With NFAT suppressed, the T-cell cannot transcribe IL-2 and other key cytokines, and the cellular immune response is broadly dampened.<\/p>\n Onset: detectable immune suppression within 1–2 days; full clinical effect in autoimmune disease at 4–8 weeks. Plasma half-life ~8–15 hours; metabolised by CYP3A4 in the liver and gut wall and excreted predominantly in bile.<\/p>\n Conimune ME is niet<\/strong> appropriate for: mild-to-moderate psoriasis or eczema (topicals first), routine RA (methotrexate first), or anyone who cannot commit to the monitoring schedule.<\/p>\n Conimune ME is supplied at 25 mg<\/strong>. Adult dose is calculated by weight and titrated to whole-blood trough cyclosporine concentration. Doses below are starting points only — the trough level guides ongoing dosing.<\/p>\n Cyclosporine therapy is impossible without regular monitoring. Skipping checks is the single most preventable cause of avoidable harm.<\/p>\n Side effects are dose-dependent and very common at therapeutic doses. The most clinically important are nephrotoxicity, hypertension and infection.<\/p>\n Common (> 10%):<\/strong><\/p>\n Uncommon to rare but serious:<\/strong><\/p>\n Cyclosporine is metabolised by CYP3A4 and is a substrate of P-glycoprotein. Hundreds of drugs interact with it. The most clinically important are listed below; any new prescription, OTC product, or herbal remedy should be checked for interaction before starting<\/strong>.<\/p>\nWaarom bestellen bij MedsBase<\/h3>\n
What Is Conimune ME?<\/h2>\n
How Does Conimune ME Work?<\/h2>\n
\n
Toepassingen en Indicaties<\/h2>\n
\n
Conimune ME Dosage and How to Take<\/h2>\n
Typical adult starting doses by indication<\/h3>\n
\n\n
\n \nIndicatie<\/th>\n Startdosis<\/th>\n Target trough (whole blood)<\/th>\n<\/tr>\n<\/thead>\n \n Renal transplant (induction)<\/td>\n 7–10 mg\/kg\/day in 2 divided doses<\/td>\n 200–300 ng\/mL early; 100–200 ng\/mL maintenance<\/td>\n<\/tr>\n \n Severe rheumatoid arthritis<\/td>\n 2.5 mg\/kg\/day in 2 divided doses; titrate to 5 mg\/kg\/day max<\/td>\n Trough not routinely measured; clinical response and toxicity guide<\/td>\n<\/tr>\n \n Severe psoriasis<\/td>\n 2.5–5 mg\/kg\/day in 2 divided doses<\/td>\n Trough not routinely measured; max 12-week courses then transition<\/td>\n<\/tr>\n \n Severe atopic dermatitis<\/td>\n 3–5 mg\/kg\/day in 2 divided doses<\/td>\n Trough not routinely measured; short-term use preferred<\/td>\n<\/tr>\n \n Nephrotic syndrome<\/td>\n 3–5 mg\/kg\/day in 2 divided doses<\/td>\n 100–200 ng\/mL<\/td>\n<\/tr>\n \n Severe ulcerative colitis (oral, after IV induction)<\/td>\n 5–8 mg\/kg\/day in 2 divided doses<\/td>\n 200–400 ng\/mL during bridge; tapered as steroid is added<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n How to Take Conimune ME Properly<\/h3>\n
\n
Monitoring Schedule<\/h2>\n
\n\n
\n \nTest<\/th>\n Frequentie<\/th>\n Action threshold<\/th>\n<\/tr>\n<\/thead>\n \n Whole-blood trough cyclosporine level<\/td>\n Weekly × 4, then every 2 weeks × 4, then monthly<\/td>\n Adjust dose to indication-specific target<\/td>\n<\/tr>\n \n Serumcreatinine + eGFR<\/td>\n Same schedule as trough<\/td>\n Rise > 30% from baseline = dose reduction or hold<\/td>\n<\/tr>\n \n Blood pressure (home or clinic)<\/td>\n Weekly × 4, then monthly<\/td>\n Sustained > 140\/90 = add or increase antihypertensive (CCBs first-line)<\/td>\n<\/tr>\n \n Serum potassium and magnesium<\/td>\n Same schedule as trough<\/td>\n High K+ or low Mg2+: dietary advice, supplementation<\/td>\n<\/tr>\n \n Fasting lipids<\/td>\n Baseline, then every 3 months<\/td>\n Elevated cholesterol\/triglycerides: dietary advice; statin (with care)<\/td>\n<\/tr>\n \n Fasting glucose \/ HbA1c<\/td>\n Baseline, then every 3 months<\/td>\n New-onset diabetes management as standard<\/td>\n<\/tr>\n \n LFTs (ALT, AST, bilirubin)<\/td>\n Baseline, then monthly × 6, then quarterly<\/td>\n Hepatocellular pattern > 3× ULN = hold and review<\/td>\n<\/tr>\n \n Skin examination<\/td>\n Baseline; annual dermatology review during long-term use<\/td>\n Any new pigmented or non-healing lesion — biopsy<\/td>\n<\/tr>\n \n Dental review<\/td>\n Baseline + every 6 months<\/td>\n Gum hyperplasia — aggressive oral hygiene + periodontal review<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Side Effects of Conimune ME<\/h2>\n
\n
\n
Waarschuwingen en voorzorgsmaatregelen<\/h2>\n
\n
Contraindications — Who Should NOT Take Conimune ME<\/h2>\n
\n
Drug Interactions — the Big Surface<\/h2>\n